McGlone Suttner Wealth Management Inc. Boosts Position in Pfizer Inc. (NYSE:PFE)

McGlone Suttner Wealth Management Inc. grew its holdings in Pfizer Inc. (NYSE:PFE) by 63.6% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 20,023 shares of the biopharmaceutical company’s stock after acquiring an additional 7,784 shares during the period. McGlone Suttner Wealth Management Inc.’s holdings in Pfizer were worth $507,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in PFE. Providence Capital Advisors LLC raised its position in Pfizer by 0.4% in the fourth quarter. Providence Capital Advisors LLC now owns 114,358 shares of the biopharmaceutical company’s stock worth $3,034,000 after acquiring an additional 409 shares in the last quarter. Donaldson Capital Management LLC raised its holdings in shares of Pfizer by 1.2% in the 4th quarter. Donaldson Capital Management LLC now owns 35,694 shares of the biopharmaceutical company’s stock worth $947,000 after purchasing an additional 410 shares in the last quarter. William B. Walkup & Associates Inc. boosted its holdings in Pfizer by 1.2% during the fourth quarter. William B. Walkup & Associates Inc. now owns 39,368 shares of the biopharmaceutical company’s stock worth $1,044,000 after buying an additional 454 shares in the last quarter. Sutton Place Investors LLC boosted its holdings in Pfizer by 5.6% during the first quarter. Sutton Place Investors LLC now owns 8,833 shares of the biopharmaceutical company’s stock worth $224,000 after buying an additional 472 shares in the last quarter. Finally, Balboa Wealth Partners grew its position in Pfizer by 1.6% in the fourth quarter. Balboa Wealth Partners now owns 30,678 shares of the biopharmaceutical company’s stock worth $814,000 after buying an additional 480 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Trading Up 0.5%

Pfizer stock opened at $25.45 on Friday. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $31.54. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.96 and a current ratio of 1.26. The firm has a market capitalization of $144.66 billion, a PE ratio of 18.44, a PEG ratio of 0.92 and a beta of 0.58. The business’s 50-day simple moving average is $23.72 and its 200-day simple moving average is $24.82.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, topping analysts’ consensus estimates of $0.67 by $0.25. The company had revenue of $13.72 billion during the quarter, compared to analyst estimates of $14.43 billion. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The company’s quarterly revenue was down 7.8% compared to the same quarter last year. During the same period in the previous year, the company earned $0.82 earnings per share. Equities research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 6.76%. The ex-dividend date of this dividend is Friday, July 25th. Pfizer’s dividend payout ratio (DPR) is presently 124.64%.

Analysts Set New Price Targets

PFE has been the subject of several research reports. UBS Group raised their price objective on Pfizer from $24.00 to $25.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 30th. Hsbc Global Res upgraded Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. BMO Capital Markets cut their price objective on Pfizer from $36.00 to $30.00 in a report on Thursday, April 17th. TD Cowen decreased their target price on shares of Pfizer from $32.00 to $28.00 and set a “hold” rating for the company in a report on Tuesday, April 22nd. Finally, HSBC dropped their target price on shares of Pfizer from $27.00 to $26.00 and set a “buy” rating on the stock in a research report on Monday, May 19th. One equities research analyst has rated the stock with a sell rating, thirteen have issued a hold rating, six have issued a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $28.55.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.